In addition, de novo cholesterol biosynthesis can promote APC/KRAS mutant CRC, along with high levels of an essential metabolite for KRAS activation, termed geranylgeranyl diphosphate (GGPP) (15). This evidence concerns the gene KRAS and colorectal carcinoma.